Aligos Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-24.2M | $-131.2M | $-87.7M | $-96.0M | $-128.3M | $-108.5M | $-52.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — |
| Depreciation | $930.0K | $1.0M | $1.6M | $2.3M | $3.0M | $2.7M | $1.4M |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $5.0M | $8.5M | $12.7M | $14.7M | $13.5M | $3.0M | $752.0K |
| Net Cash from Operating Activities | $-82.5M | $-80.7M | $-79.0M | $-79.4M | $-115.7M | $-74.3M | $-46.8M |
| Investing Activities | |||||||
| Capital Expenditures | — | $130.0K | $19.0K | $943.0K | $892.0K | $2.1M | $2.8M |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-37.8M | $-18.3M | $45.0M | $-26.3M | $3.0M | $32.8M | $6.8M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $101.6M | $355.0K | $88.3M | $164.0K | $78.7M | $192.3M | $85.5M |
| Net Change in Cash | — | — | — | — | — | — | — |
| Free Cash Flow | — | $-80.9M | $-79.0M | $-80.3M | $-116.6M | $-76.3M | $-49.6M |